---
title: "Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.82, Implies 94% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295550601.md"
description: "Tyra Biosciences' average 12-month price target was lowered from $51.09 to $50.82 by 11 analysts, with forecasts ranging between $39 and $59. Based on the August 10 closing price, this implies a 94% upside potential. The consensus rating remains 'Buy', supported by 14 buy ratings, one hold, and no sell ratings among the 15 covering analysts."
datetime: "2026-08-11T14:20:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295550601.md)
  - [en](https://longbridge.com/en/news/295550601.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295550601.md)
generator: "portal-rs"
---

# Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.82, Implies 94% Upside

-   According to estimates from 11 analysts, Tyra Biosciences, Inc. stock's average price target has fallen from $51.09 to $50.82, with forecasts ranging from $39 to $59 per share
-   Based on the Aug. 10 closing price, the updated target implies approximately 94% potential upside
-   Consensus rating remains at “Buy” across 15 covering analysts, with 14 Buys, 1 Holds and 0 Sells

Explore more price target data and ratings for Tyra Biosciences, Inc. on the , and track all previous and future analyst recommendations for Tyra Biosciences, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [TYRA.US](https://longbridge.com/en/quote/TYRA.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Tyra Biosciences: Buy Rating Reiterated as SURF302 Data Upside Beckons; 12‑Month Price Target Maintained at $45](https://longbridge.com/en/news/298055291.md)
- [Tyra Biosciences to present initial Phase 2 SURF302 data for oral dabogratinib in intermediate-risk bladder cancer on Sept. 9](https://longbridge.com/en/news/298034950.md)
- [Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA](https://longbridge.com/en/news/295998857.md)
- [FY2028 EPS Estimates for Upstream Bio Decreased by Analyst](https://longbridge.com/en/news/298028139.md)
- [VanadiumCorp Announces Grant of Stock Options](https://longbridge.com/en/news/298078922.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**